VWA
BCRX icon

Visionary Wealth Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Visionary Wealth Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$169K Sell
16,890
-3,000
-15% -$27.1K 0.01% 648
2026
Q1 		$189K Sell
19,890
-200
-1% -$1.55K 0.01% 620
2025
Q4 		$157K Hold
20,090
– – 0.01% 597
2025
Q3 		$152K Sell
20,090
-3,000
-13% -$25K 0.01% 583
2025
Q2 		$207K Sell
23,090
-3,500
-13% -$32.6K 0.01% 552
2025
Q1 		$199K Hold
26,590
– – 0.01% 522
2024
Q4 		$200K Sell
26,590
-1,200
-4% -$9.11K 0.01% 521
2024
Q3 		$211K Sell
27,790
-450
-2% -$3.42K 0.01% 503
2024
Q2 		$175K Sell
28,240
-300
-1% -$1.66K 0.01% 492
2024
Q1 		$145K Hold
28,540
– – 0.01% 475
2023
Q4 		$171K Sell
28,540
-5,000
-15% -$29K 0.01% 462
2023
Q3 		$237K Sell
33,540
-5,000
-13% -$35.9K 0.02% 406
2023
Q2 		$271K Sell
38,540
-1,400
-4% -$11.2K 0.02% 380
2023
Q1 		$333K Buy
39,940
+140
+0.4% +$1.35K 0.03% 335
2022
Q4 		$457K Buy
39,800
+750
+2% +$9.35K 0.04% 252
2022
Q3 		$492K Sell
39,050
-5,400
-12% -$69.5K 0.05% 229
2022
Q2 		$470K Buy
44,450
+4,950
+13% +$51.1K 0.04% 246
2022
Q1 		$642K Sell
39,500
-5,625
-12% -$90.2K 0.05% 223
2021
Q4 		$625K Buy
45,125
+3,650
+9% +$48.3K 0.05% 208
2021
Q3 		$596K Buy
41,475
+15,275
+58% +$241K 0.06% 172
2021
Q2 		$414K Buy
26,200
+8,000
+44% +$109K 0.04% 221
2021
Q1 		$185K Buy
+18,200
New +$188K 0.02% 310

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Visionary Wealth Advisors's BCRX Position: Q2 2026 in Review

Visionary Wealth Advisors reduced its BioCryst Pharmaceuticals (BCRX) stake by 15% in Q2 2026, selling an estimated $27.1K and leaving 16,890 shares worth $169K. The position accounts for 0.01% of the portfolio, ranked #648.

Visionary Wealth Advisors first reported a position in BCRX in Q1 2021 and has held it in 22 quarters since. The position peaked at $642K in Q1 2022. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Visionary Wealth Advisors held 16,890 shares of BioCryst Pharmaceuticals worth $169K as of Q2 2026.
  • Visionary Wealth Advisors sold 3,000 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $27.1K.
  • BioCryst Pharmaceuticals made up 0.01% of Visionary Wealth Advisors's portfolio in Q2 2026, its #648 holding.
  • Visionary Wealth Advisors first reported a position in BioCryst Pharmaceuticals in Q1 2021 and has held it in 22 quarters since.
  • Visionary Wealth Advisors's BioCryst Pharmaceuticals position peaked at $642K in Q1 2022.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Visionary Wealth Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.